Connect with us

AI Is Booming: 2 ‘Strong Buy’ Stocks That Stand to Benefit

AI Is Booming: 2 ‘Strong Buy’ Stocks That Stand to Benefit

Published

on

This article was originally published by TipRanks.

The COVID pandemic may be receding, but it has left a mark on across multiple aspects of our lives. From mask mandates to travel restrictions, we chafe at some of the changes – but in the business world the use of artificial intelligence (AI) systems has dramatically expanded in the past year. This was probably inevitable – but AI brought advantages in coping with the pandemic for companies that could make use of it, and the expansion accelerated.

AI has found its place in a huge range of applications, at both the front and back end of businesses. It’s prevalent in software management and data systems, as well as in communications, where AI systems filter emails and conduct robochats.

And this has not been ignored by Wall Street. Analysts say that plenty of compelling investments can be found within this space. With this in mind, we’ve opened up TipRanks’ database, and pulled two stocks which are stand to benefit from AI technology. Importantly, both have amassed enough bullish calls from analysts to be given “Strong Buy” consensus ratings.

Nuance Communications (NUAN)

We’ll start with Nuance, a company in the communications software niche. This Massachusetts-based company offers solutions for business clients in the healthcare and customer service industries, with products that enhance speech recognition, telephone call steering systems, automated phone directories, medical transcription, and optical character recognition. It’s a full range of AI-powered, cloud communications software, applied in real time.

Nuance’s flagship product, the Dragon Ambient eXperience (DAX) is marketed to the healthcare industry, where it uses AI to automate the paperwork burdens on physician practices and hospitals. This streamlines operations allow doctors more time and resources to spend on patients, and provides greater satisfaction to health care providers and users.

The applications of Nuance’s product and solution lines to the current environment is clear: when the pandemic locked down so many people at home, businesses still had to maintain their customer-facing systems, and software automation, based on AI tech, made that possible with fewer personnel. Since the pandemic started last winter, the company seen its shares grow tremendously, up 205% in the last 12 months, far outpacing the overall stock market.

The most recent quarterly report, for fiscal Q1, showed quarterly revenues above the forecast at $81.4 million. EPS showed a net loss, as expected, but at 27 cents the loss was a 28% sequential improvement from Q3. The company’s balance sheet is strong, with zero debt, $256 million cash on hand, and a credit facility up to $50 million.

The company’s most recent quarterly report, for fiscal Q1, beat the forecasts on both the top and bottom lines. Earnings beat expectations by 11%, coming in at 20 cents per share, while revenues of $345.8 million were a modest 2% above the estimates. As a result, operating cash flow grew 22% year-over-year, to $54.6 million for the quarter.

Among the bulls is 5-star analyst Daniel Ives, of Wedbush, who rates NUAN shares an Outperform (i.e. Buy), and his $65 price target implies an upside potential of ~44%. (To watch Ives’ track record, click here)

"We believe Nuance overall continues to be laser focused on building a global cloud healthcare and AI driven business with growing ARR and a sustainable revenue/ earnings stream going forward with larger deals in the field as more hospital- wide deployments shift to the cloud are playing out and gaining further momentum based on our checks," Ives opined.

The analyst added, "From a valuation/ SOTP perspective, we believe over time the DAX business alone could be worth between $3 billion to $4 billion to NUAN's stock as this AI next generation platform represents a potential paradigm changer for hospitals/healthcare clinics/specialists over the coming years."

Ives is no outlier on Nuance, as shown by the unanimous Strong Buy analyst consensus on the stock. Nuance has received 6 recent reviews, and all are to Buy. The shares are trading for $45.20, and the $59.67 average price target suggests a 32% one-year upside. (See NUAN stock analysis on TipRanks)

Dynatrace, Inc. (DT)

The second AI stock we’ll look at, Dynatrace, is another cloud software company – but Dynatrace’s products are designed to power business data. The company’s AI platform brings intelligent automation to network management and cloud monitoring. DT’s platform allows for cloud automation, business analytics, digital experience, application security, applications and microservices, and infrastructure monitoring. It’s sold as a one-stop-shop for network and system managers seeking an intelligent software agent.

Dynatrace’s shares have been showing consistent growth over a long term. The stock is up a robust 133% in the past 12 months, and revenues have also been growing over that period.

In the most recent report, for Q3 fiscal year 2021, the company showed $182.9 million in top-line revenue, beating the forecast by ~6% and growing 27% year-over-year. EPS came in at 6 cents, flat from Q2 and far better than the break-even reported for the year-ago quarter.

Three key metrics stand out in the quarterly report, and both for the right reasons. Subscription revenue grew 33% year-over-year, to reach $170.3 million, and annual recurring revenue (ARR) – which is an important predictor of future performance – grew 35% yoy and came in at $722 million. At the same time, license revenue dropped by more than 93%, to just $300,000. Taken all together, these results point toward a strong shift toward recurring cloud customers – a common trend in the software space.

Needham’s 5-star analyst Jack Andrews has been closely following Dynatrace, and he believes DT’s AI products may replace incumbent tools as customers expand to additional modules.

“Embedded AIOps and automation creates a compelling value proposition… Compared to competitors in the market, DT's AI Engine is embedded within its core platform and can be levered across the portfolio to deliver answers from data. Moreover, its One Agent technology automatically discovers high-fidelity data from applications and thus can map the billions of dependencies in complex environments," Andrews said.

The analyst summed up, "In our view, DT is well-positioned to serve as a single source of truth that can help users trace a line between written code and business outcomes (i.e. BizDevSecOps)."

Andrews named Dynatrace as a top pick, and in line with this upbeat assessment, the analyst rates the stock a Buy along with a $66 price target. Ivestors stand to pocket ~28% gain should the analyst's thesis play out. (To watch Andrews’ track record, click here)

Once again, we’re looking at a stock who strong performance has inspired unanimity from the Wall Street analysts. DT shares have 13 Buy reviews, for a Strong Buy consensus rating. The stock sells for $51.76 and its $59.69 average price target suggests ~15% upside from that level. (See DT stock analysis on TipRanks)

To find good ideas for AI stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

The post AI Is Booming: 2 ‘Strong Buy’ Stocks That Stand to Benefit appeared first on TipRanks Financial Blog.

Read More

Continue Reading

Spread & Containment

SoCal Industrial Prioritizes Speed, Power and Sustainability 

Movement is key in the SoCal industrial space. Industrial real estate occupies some 200 million square feet of space in the SoCal region, with much of…

Published

on

Movement is key in the SoCal industrial space. Industrial real estate occupies some 200 million square feet of space in the SoCal region, with much of the activity driven by the Ports of L.A. and Long Beach. The swift movement – not storage – of goods from the port to their destinations, is priority. Currently, the industrial vacancy rate sits at 4%. While the increase in e-commerce during the COVID-19 pandemic caused industrial volume in the region to surge, volumes have declined 30% over the past year, returning to more normal, though still high, levels comparable to 2019.  

Attendees of I.CON West in Long Beach, California, had the opportunity to visit three impressive industrial properties in the SoCal region. The projects by Goodman, Watson Land Company and Bridge Industrial are in three different phases of completion and range in size from 165,000-500,000 square feet. 

The I.CON West group toured a 90-acre site in Long Beach purchased by Goodman, a globally traded real estate company, five years ago. The Goodman Commerce Center Long Beach was previously a Boeing manufacturing center with 100-foot clear heights that made it well suited for the current tenant Relativity, a company that makes 3-D printed rockets.  

Power is a major consideration for tenants in the region. Tenants are also asking for clear heights that are increasingly taller; the typical height in 2012 was closer to 32 feet, but buildings in the area are inching closer to the 40-foot range.  

Environmental concerns are top of mind in California. Long Beach requires a methane mitigation system and Boeing also required a vapor barrier to be added to the site as part of their land use covenant. The area was previously heavily comprised of oil fields, so vapor barriers are common. The state is working toward a 2035 goal of having 100% of new cars and light trucks sold in California be zero-emission vehicles, so sites are considering the current usage and future expansion of EV charging stations. Goodman’s site is equipped with 26 EV-charging stations but has the capability to expand to 100 more, as needs require. 

Watson Land Company’s site in Carson, California, is located in the South Bay, an area that includes many 1980s-era Class B buildings that are being redeveloped to meet modern usage and demand.  

One of the main challenges faced in this area is the heavy clay soil; Watson had to install an underground storm drain system to allow for percolation.  

One of the main advantages of the area is that it’s within the “Overweight Container Corridor” that allows for heavier vehicles – up to 95,000 pounds – to pass through with containers from the port.  

Watson Land Company is pursuing U.S. Green Building Council LEED Gold certification for this site; they were able to reuse or recycle 98.6% of the material crushed from the previous buildings. The company aims for LEED Silver or Gold in many of their buildings in California, part of its early legacy dating to the founding of Watson Land Company in 1912 with a commitment to serve as “good stewards of the land.” 

Another feature of the Watson Land Company’s building: ample skylights – a 3% skylight to roof ratio – and clerestory windows to bring in maximum natural light. 

For the final stop of the tour, attendees visited a former brownfield site in Torrance, California, developed by Bridge Industrial. Bridge Industrial considers their team problem solvers who can tackle sites like this one that require significant remediation. They have transformed the brownfield site into a modern, airy industrial facility with two stories of office space.  

Power, again, came up as a critical concern for tenants. Bridge Industrial used to provide 2,000 amps as the standard but now provides 4,000 amps as the new standard in response to tenant needs. One of Bridge Industrial’s buildings in Rancho Cucamonga (roughly a two-hour drive east from Long Beach) offers 4,000 amps with provisions for additional future service up to an astonishing 8,000 amps.   

With the dual ports and the LAX airport nearby, SoCal is poised to continue its strong industrial presence. Port activity, environmental regulations and evolving tenant demands – including for increasing power capabilities – are critical considerations for developers, owners and investors operating in this bustling region.


This post is brought to you by JLL, the social media and conference blog sponsor of NAIOP’s I.CON West 2024. Learn more about JLL at www.us.jll.com or www.jll.ca.

Read More

Continue Reading

International

Chronic stress and inflammation linked to societal and environmental impacts in new study

From anxiety about the state of the world to ongoing waves of Covid-19, the stresses we face can seem relentless and even overwhelming. Worse, these stressors…

Published

on

From anxiety about the state of the world to ongoing waves of Covid-19, the stresses we face can seem relentless and even overwhelming. Worse, these stressors can cause chronic inflammation in our bodies. Chronic inflammation is linked to serious conditions such as cardiovascular disease and cancer – and may also affect our thinking and behavior.   

Credit: Image: Vodovotz et al/Frontiers

From anxiety about the state of the world to ongoing waves of Covid-19, the stresses we face can seem relentless and even overwhelming. Worse, these stressors can cause chronic inflammation in our bodies. Chronic inflammation is linked to serious conditions such as cardiovascular disease and cancer – and may also affect our thinking and behavior.   

A new hypothesis published in Frontiers in Science suggests the negative impacts may extend far further.   

“We propose that stress, inflammation, and consequently impaired cognition in individuals can scale up to communities and populations,” explained lead author Prof Yoram Vodovotz of the University of Pittsburgh, USA.

“This could affect the decision-making and behavior of entire societies, impair our cognitive ability to address complex issues like climate change, social unrest, and infectious disease – and ultimately lead to a self-sustaining cycle of societal dysfunction and environmental degradation,” he added.

Bodily inflammation ‘mapped’ in the brain  

One central premise to the hypothesis is an association between chronic inflammation and cognitive dysfunction.  

“The cause of this well-known phenomenon is not currently known,” said Vodovotz. “We propose a mechanism, which we call the ‘central inflammation map’.”    

The authors’ novel idea is that the brain creates its own copy of bodily inflammation. Normally, this inflammation map allows the brain to manage the inflammatory response and promote healing.   

When inflammation is high or chronic, however, the response goes awry and can damage healthy tissues and organs. The authors suggest the inflammation map could similarly harm the brain and impair cognition, emotion, and behavior.   

Accelerated spread of stress and inflammation online   

A second premise is the spread of chronic inflammation from individuals to populations.  

“While inflammation is not contagious per se, it could still spread via the transmission of stress among people,” explained Vodovotz.   

The authors further suggest that stress is being transmitted faster than ever before, through social media and other digital communications.  

“People are constantly bombarded with high levels of distressing information, be it the news, negative online comments, or a feeling of inadequacy when viewing social media feeds,” said Vodovotz. “We hypothesize that this new dimension of human experience, from which it is difficult to escape, is driving stress, chronic inflammation, and cognitive impairment across global societies.”   

Inflammation as a driver of social and planetary disruption  

These ideas shift our view of inflammation as a biological process restricted to an individual. Instead, the authors see it as a multiscale process linking molecular, cellular, and physiological interactions in each of us to altered decision-making and behavior in populations – and ultimately to large-scale societal and environmental impacts.  

“Stress-impaired judgment could explain the chaotic and counter-intuitive responses of large parts of the global population to stressful events such as climate change and the Covid-19 pandemic,” explained Vodovotz.  

“An inability to address these and other stressors may propagate a self-fulfilling sense of pervasive danger, causing further stress, inflammation, and impaired cognition in a runaway, positive feedback loop,” he added.  

The fact that current levels of global stress have not led to widespread societal disorder could indicate an equally strong stabilizing effect from “controllers” such as trust in laws, science, and multinational organizations like the United Nations.   

“However, societal norms and institutions are increasingly being questioned, at times rightly so as relics of a foregone era,” said Prof Paul Verschure of Radboud University, the Netherlands, and a co-author of the article. “The challenge today is how we can ward off a new adversarial era of instability due to global stress caused by a multi-scale combination of geopolitical fragmentation, conflicts, and ecological collapse amplified by existential angst, cognitive overload, and runaway disinformation.”    

Reducing social media exposure as part of the solution  

The authors developed a mathematical model to test their ideas and explore ways to reduce stress and build resilience.  

“Preliminary results highlight the need for interventions at multiple levels and scales,” commented co-author Prof Julia Arciero of Indiana University, USA.  

“While anti-inflammatory drugs are sometimes used to treat medical conditions associated with inflammation, we do not believe these are the whole answer for individuals,” said Dr David Katz, co-author and a specialist in preventive and lifestyle medicine based in the US. “Lifestyle changes such as healthy nutrition, exercise, and reducing exposure to stressful online content could also be important.”  

“The dawning new era of precision and personalized therapeutics could also offer enormous potential,” he added.  

At the societal level, the authors suggest creating calm public spaces and providing education on the norms and institutions that keep our societies stable and functioning.  

“While our ‘inflammation map’ hypothesis and corresponding mathematical model are a start, a coordinated and interdisciplinary research effort is needed to define interventions that would improve the lives of individuals and the resilience of communities to stress. We hope our article stimulates scientists around the world to take up this challenge,” Vodovotz concluded.  

The article is part of the Frontiers in Science multimedia article hub ‘A multiscale map of inflammatory stress’. The hub features a video, an explainer, a version of the article written for kids, and an editorial, viewpoints, and policy outlook from other eminent experts: Prof David Almeida (Penn State University, USA), Prof Pietro Ghezzi (University of Urbino Carlo Bo, Italy), and Dr Ioannis P Androulakis (Rutgers, The State University of New Jersey, USA). 


Read More

Continue Reading

International

Acadia’s Nuplazid fails PhIII study due to higher-than-expected placebo effect

After years of trying to expand the market territory for Nuplazid, Acadia Pharmaceuticals might have hit a dead end, with a Phase III fail in schizophrenia…

Published

on

After years of trying to expand the market territory for Nuplazid, Acadia Pharmaceuticals might have hit a dead end, with a Phase III fail in schizophrenia due to the placebo arm performing better than expected.

Steve Davis

“We will continue to analyze these data with our scientific advisors, but we do not intend to conduct any further clinical trials with pimavanserin,” CEO Steve Davis said in a Monday press release. Acadia’s stock $ACAD dropped by 17.41% before the market opened Tuesday.

Pimavanserin, a serotonin inverse agonist and also a 5-HT2A receptor antagonist, is already in the market with the brand name Nuplazid for Parkinson’s disease psychosis. Efforts to expand into other indications such as Alzheimer’s-related psychosis and major depression have been unsuccessful, and previous trials in schizophrenia have yielded mixed data at best. Its February presentation does not list other pimavanserin studies in progress.

The Phase III ADVANCE-2 trial investigated 34 mg pimavanserin versus placebo in 454 patients who have negative symptoms of schizophrenia. The study used the negative symptom assessment-16 (NSA-16) total score as a primary endpoint and followed participants up to week 26. Study participants have control of positive symptoms due to antipsychotic therapies.

The company said that the change from baseline in this measure for the treatment arm was similar between the Phase II ADVANCE-1 study and ADVANCE-2 at -11.6 and -11.8, respectively. However, the placebo was higher in ADVANCE-2 at -11.1, when this was -8.5 in ADVANCE-1. The p-value in ADVANCE-2 was 0.4825.

In July last year, another Phase III schizophrenia trial — by Sumitomo and Otsuka — also reported negative results due to what the company noted as Covid-19 induced placebo effect.

According to Mizuho Securities analysts, ADVANCE-2 data were disappointing considering the company applied what it learned from ADVANCE-1, such as recruiting patients outside the US to alleviate a high placebo effect. The Phase III recruited participants in Argentina and Europe.

Analysts at Cowen added that the placebo effect has been a “notorious headwind” in US-based trials, which appears to “now extend” to ex-US studies. But they also noted ADVANCE-1 reported a “modest effect” from the drug anyway.

Nonetheless, pimavanserin’s safety profile in the late-stage study “was consistent with previous clinical trials,” with the drug having an adverse event rate of 30.4% versus 40.3% with placebo, the company said. Back in 2018, even with the FDA approval for Parkinson’s psychosis, there was an intense spotlight on Nuplazid’s safety profile.

Acadia previously aimed to get Nuplazid approved for Alzheimer’s-related psychosis but had many hurdles. The drug faced an adcomm in June 2022 that voted 9-3 noting that the drug is unlikely to be effective in this setting, culminating in a CRL a few months later.

As for the company’s next R&D milestones, Mizuho analysts said it won’t be anytime soon: There is the Phase III study for ACP-101 in Prader-Willi syndrome with data expected late next year and a Phase II trial for ACP-204 in Alzheimer’s disease psychosis with results anticipated in 2026.

Acadia collected $549.2 million in full-year 2023 revenues for Nuplazid, with $143.9 million in the fourth quarter.

Read More

Continue Reading

Trending